Results for "Bakkt"

Bakkt (BKKT) made available the transcript of its Q2 2026 earnings call, covering its financial results and operational highlights for the quarter.

A summary of Bakkt Holdings, Inc.'s earnings call for the second quarter of 2026 has been released.

Bakkt is targeting $2.5 billion in total transacting volume by 2026 as its DTR integrations continue to progress.

CAAP has made available the transcript from its fourth-quarter 2025 earnings call, detailing the company's financial performance and outlook.

36Kr Holdings announced its GAAP EPADS of $0.753 and revenue of $25.69 million for the fourth quarter.

Cryptocurrency company Nexo is making a return to the U.S. market, announcing a strategic partnership with digital asset platform Bakkt.

Bakkt has announced the appointment of a new Chief Financial Officer, a move aimed at strengthening the company's efforts to expand its stablecoin offerings and market presence.

Several companies, including Casella, Matthews, Grove, Blend, Maravai, and iRhythm, have released their financial outlooks for 2026. These projections detail anticipated revenues and adjusted EBITDA ranges, with some noting strategic expansions and cautious modeling.

Bakkt's stock has slumped after its first-quarter earnings declined, coinciding with the company's strategic pivot towards stablecoin infrastructure.

W&T Offshore released its earnings transcript for the fourth quarter of 2025.

An article presents a preview of Bakkt Holdings' financial performance before its fourth-quarter 2025 earnings release.

Nexo plans its US return after an SEC settlement, while a new report highlights cryptocurrency's increasing role in human trafficking networks.

FingerMotion, Inc. has appointed Chris Polimeni as its new Chief Financial Officer, while Bakkt has named Matt White as CFO to lead its next phase of global growth.

Bakkt is focusing on stablecoin payments as a strategic move after experiencing a significant drop in its first-quarter revenue.

Analysts are preparing for the upcoming Q1 2026 earnings report from Bakkt Holdings and the Q2 2026 earnings report from Vertex Pharmaceuticals. These previews offer insights into expected financial performance for both companies.

Bakkt Holdings, Inc. has announced that it will be unable to file its annual Form 10-K for the fiscal year 2025 by the deadline.

Bakkt has priced a registered direct offering totaling $48.1 million.